Effect of Nuts on Gastrointestinal Health

“

TL;DR

This narrative review summarizes evidence on how nuts affect gastrointestinal health, focusing on their limited upper-GI digestion and delivery of undigested nutrients to the colon. While some studies suggest nut consumption may increase fecal butyrate (especially from almonds) and that walnuts may protect against ulcerative colitis and gastric lesions, clinical trials on gut microbiota changes remain inconclusive. The review highlights that cell wall structure, particle size, and processing methods critically influence nutrient bioaccessibility and subsequent microbial fermentation.

Full summary

5,069 CHARS

**Background:** Nuts are nutrient-dense foods rich in healthy lipids, dietary fiber, and bioactive phytochemicals. While their cardiometabolic benefits are well documented, evidence on gastrointestinal health is less established. The unique cellular structure of nuts—intact cell walls, lipid encapsulation, and high dietary fiber content—means that a significant fraction of nutrients and phytochemicals resist digestion in the upper gastrointestinal tract and reach the colon, where they can be fermented by gut microbiota. This narrative review summarizes current knowledge on the digestion of nuts, their impact on gut microbiota composition and diversity, microbial end-products (short-chain fatty acids and bile acids), and potential protective effects against gastrointestinal diseases.

**Methods:** The authors conducted a narrative review of the literature, covering studies on nut microstructure, in vitro and in vivo digestion models, clinical trials assessing gut microbiota changes, and preclinical models of gastrointestinal disease. Key studies cited include systematic reviews and meta-analyses of randomized controlled trials (RCTs) on nut consumption and fecal microbiota, as well as individual clinical trials on almonds, walnuts, pistachios, and peanuts. The review also discusses the effects of processing (roasting, blanching) and food matrices on nutrient bioaccessibility.

**Key Results:** - **Bioaccessibility:** Mechanical breakdown (chewing or grinding) is essential to rupture nut cells and release intracellular lipids and proteins. A theoretical model predicted that ground almonds have greater lipid bioaccessibility than whole almonds after mastication (10.4% ± 1.8% vs. 9.3% ± 2.0%; p = 0.017). Roasting can cause lipid coalescence and make tissues more brittle, potentially enhancing mastication efficiency. - **Polyphenol bioaccessibility:** Only about 5–10% of total polyphenol intake is absorbed in the small intestine; the remainder reaches the colon. Polyphenols from pistachios are bioaccessible with small differences between raw and roasted forms. Almond polyphenol metabolites (e.g., naringenin, (epi)catechin, isorhamnetin conjugates) have been identified in plasma and urine at nanomolar concentrations. - **Microbiota diversity:** The effect of nut consumption on alpha-diversity (within-sample diversity) and beta-diversity (between-sample diversity) has been inconsistent. One 8-week almond intervention reported significant changes in Chao-1 and Shannon indices, while a walnut intervention of similar length did not change the Simpson index. Beta-diversity results varied: two almond studies found no effect, one reported an increase, and two walnut studies reported increased beta-diversity. - **Phyla-level changes:** A meta-analysis of seven interventions (five almond, one walnut) found no significant effects of nut intake on the relative abundance of Actinobacteria, Bacteroidetes, Firmicutes, Proteobacteria, or Verrucomicrobia. - **Genus-level changes:** Nut consumption increased the relative abundance of Clostridium, Dialister, Lachnospira, and Roseburia, and decreased Parabacteroides. However, these effects were influenced by study design (crossover vs. parallel), nut type, and duration. - **Short-chain fatty acids (SCFAs):** In a study of 87 subjects consuming 56 g/d of almonds for 4 weeks, fecal butyrate was higher when data from whole and ground almonds were combined compared with controls. A 6-month peanut study (25 g/d peanuts or 32 g/d peanut butter) increased fecal acetate, propionate, and butyrate versus baseline. A 3-day walnut intervention increased SCFA levels and butyrate-producing bacteria (Coprococcus, Anaerostipes). - **Bile acids:** In 18 subjects consuming 42 g/d walnuts for 3 weeks, fecal secondary bile acid concentrations were significantly lower compared with a control diet. - **Gastrointestinal disease:** Preclinical studies show that walnut constituents (ellagitannins, urolithins, alpha-linolenic acid) reduce inflammation in models of ulcerative colitis and gastric mucosal lesions. Walnut supplementation protected colonic mucosa in DSS-induced colitis and reduced gastric cancer frequency in an H. pylori model.

**Clinical Implications:** The review underscores that nut consumption may beneficially modulate gut microbiota and microbial metabolites, but current evidence is insufficient to draw firm conclusions. The inconsistent findings highlight the need for well-powered, longer-duration RCTs that control for baseline diet, nut type, dose, and processing. The potential for walnuts to protect against inflammatory bowel disease and gastric lesions is promising but requires confirmation in human trials. Clinicians should be aware that the energy content of nuts is overestimated by standard calculations (5–25% lower metabolizable energy), which may have implications for dietary counseling. Future research should focus on functional and clinical outcomes, including disease endpoints, and consider inter-individual variability in microbiome composition.